TTC-352
TTC-352 is an orally bioavailable selective human estrogen receptor (ER) α partial agonist (ShERPA) . TTC-352 inhibits the growth of three ER+ breast cancer cells. TTC-352 induces tumor regression accompanied by exit of ERα from the nucleus to extranuclear sites[1][2].
Product Specifications
CAS Number
[1607819-68-0]
UNSPSC
12352005
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ttc-352.html
Smiles
OC1=CC=C(C(C2=CC=C(F)C=C2)=C(OC3=CC=C(O)C=C3)S4)C4=C1
Molecular Formula
C20H13FO3S
Molecular Weight
352.38
References & Citations
[1]Tonetti D A, et al. Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer[J]. 2017.|[2]Molloy ME, et al. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther. 2014 Nov;13 (11) :2515-26.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-126932/TTC-352-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-126932/
Scientific Category
Reference compound1
Clinical Information
Phase 1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1075230-01 0.02 mg (E-Coli)
Recombinant Mycobacterium sp. Putative phosphoserine aminotransferase (serC)
Ask
View Details 
MBS1075230-02 0.02 mg (Yeast)
Recombinant Mycobacterium sp. Putative phosphoserine aminotransferase (serC)
Ask
View Details MBS1075230-03 0.1 mg (E-Coli)
Recombinant Mycobacterium sp. Putative phosphoserine aminotransferase (serC)
Ask
View Details MBS1075230-04 0.1 mg (Yeast)
Recombinant Mycobacterium sp. Putative phosphoserine aminotransferase (serC)
Ask
View Details MBS1075230-05 0.02 mg (Baculovirus)
Recombinant Mycobacterium sp. Putative phosphoserine aminotransferase (serC)
Ask
View Details